CurrentBlue Cross Blue Shield - MassachusettsPolicy 551

Serologic antibody testing (ANCA/ASCA) for inflammatory bowel disease

This policy governs coverage and prior authorization requirements for serum testing of anti-neutrophil cytoplasmic antibody (ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) in the diagnosis and monitoring of inflammatory bowel disease for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySerologic antibody testing (ANCA/ASCA) for inflammatory bowel disease

Policy CodePolicy 551

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

10-15%Uncertain IBD cases

High specificityTest performance

InpatientAuth required if

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational - Not covered as medically necessary

Coverage determination

Investigational statement: All serum antibody testing (ANCA and ASCA) for the diagnosis and monitoring of inflammatory bowel disease is considered investigational regardless of commercial name, manufacturer, or FDA approval status.

Policy states investigational status and lack of demonstrated clinical utility.

Outpatient serum testing for anti-neutrophil cytoplasmic antibody (ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, and Medicare PPO BlueSM members. Precertification/preauthorization is required if the procedure is performed inpatient; when reporting services, providers should use current procedure, revenue, and diagnosis codes and follow applicable precertification/preauthorization rules.

Systematic reviews report that ANCA/ASCA assays have relatively low sensitivity and moderately high specificity. Importantly, the literature does not demonstrate clinical utility for these tests: no studies showed they can replace standard diagnostic workup for inflammatory bowel disease or reduce the number of invasive procedures. Because impact on net health outcome is insufficiently supported, these serologic tests are considered investigational and not medically necessary for diagnosis or monitoring of IBD.

Precertification and Billing Guidance

Prior Authorization

Prior Authorization Required

Precertification/Preauthorization is required for all inpatient procedures described in this policy. Outpatient ANCA/ASCA testing is not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, and Medicare PPO (Bluesm).

Inpatient procedures: prior authorization required for all products when performed inpatient.
Outpatient procedures: ANCA/ASCA testing is not covered across listed commercial and Medicare products.

Billing Rule

Coding and Precertification Note

Providers must report all services using current, industry-standard procedure, revenue, and diagnosis codes (including appropriate modifiers). Follow the payer's precertification and billing rules when submitting claims to avoid denials.

Use up-to-date CPT/HCPCS and ICD-10 codes and applicable modifiers.
Ensure prior authorization numbers are included on claims for inpatient procedures where required.

Note

Provider Action Summary

This section highlights provider actions and billing guidance related to coverage and authorization. Confirm member-specific benefits and the member's contract at the time of service to determine coverage or non-coverage.

Verify member benefits before scheduling services.
Documentation of medical necessity may be required to support prior authorization requests.

Background and Clinical Context

Inflammatory bowel disease (IBD) encompasses ulcerative colitis and Crohn’s disease and is diagnosed primarily by radiographic, endoscopic, and histologic evaluation. In about 10–15% of cases, the distinction between ulcerative colitis and Crohn’s disease remains uncertain. Two serum antibodies—ANCA (anti‑neutrophil cytoplasmic antibody) and ASCA (anti‑Saccharomyces cerevisiae antibody)—have been associated with IBD and proposed as adjuncts for diagnosis, subclassification, prognosis, or prediction of treatment response. However, systematic reviews show these assays do not have adequate sensitivity and their clinical utility (for example, substituting for standard workup or decreasing invasive testing) has not been demonstrated; accordingly, use of these tests does not currently change recommended diagnostic pathways.

Key Definitions

Anti-neutrophil cytoplasmic antibody (ANCA) definition

TermAnti-neutrophil cytoplasmic antibody (ANCA)

AssociationSerum antibody associated with inflammatory bowel disease (IBD)

Proposed clinical usesDiagnostic adjunct for IBD, differentiating ulcerative colitis vs Crohn's disease in indeterminate cases, subclassifying disease location or severity, prognostic marker, and potential predictor of treatment response or familial susceptibility

Coverage stanceAll serum antibody testing (ANCA) for diagnosis of IBD is considered investigational regardless of commercial name, manufacturer, or FDA status

Diagnostic contextDefinitive IBD diagnosis typically established by radiographic, endoscopic, and histologic criteria; ANCA proposed as adjunctive serologic test

Anti-Saccharomyces cerevisiae antibody (ASCA) definition

TermAnti-Saccharomyces cerevisiae antibody (ASCA)

AssociationSerum antibody associated with inflammatory bowel disease (IBD)

Proposed clinical usesDiagnostic adjunct for IBD, aiding differentiation of ulcerative colitis vs Crohn's disease in indeterminate cases, subclassification by disease location or severity, prognostic information, and potential predictor of treatment response or familial susceptibility

Coverage stanceAll serum antibody testing (ASCA) for diagnosis of IBD is considered investigational regardless of commercial name, manufacturer, or FDA status

Diagnostic contextDefinitive IBD diagnosis usually by radiographic, endoscopic, and histologic criteria; ASCA considered an adjunctive serologic marker

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySerologic antibody testing (ANCA/ASCA) for inflammatory bowel disease

Policy CodePolicy 551

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

On This Page